Справка за цитирания на научни публикации с участието на доц. д-р Красимира Тодорова-Хайрабедян, публикувани в международни, рецензирани и индексирани списания и книги – до 2017:

Общ брой цитирания: **124**

Справката за цитиранията е направена с помощта на Scopus, ISI Thomson Research и Google Scholar (Harzing's Publish or Perish), ***без явни и скрити автоцитирания***.

https://scholar.google.bg/citations?user=iO-vKU8AAAAJ&hl=en

Цитирана публикация:

1. **Todorova, K**., Ignatova, I., Tchakarov, S., Altankova, I., Zoubak, S., Kyurkchiev, S. and Mincheff, M. (**2005**) 'Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.', *Cancer immunity*, 5, p. 1. doi: 040913 [pii].

е цитирана от (48):

1.1. Smith MH. Queens, New York 11418, USA mark20082009@ gmail. com. Head Neck Surg [Internet]. cancerbio.net; 129(12):1317–21. Available from: http://www.cancerbio.net/cb/cb0104/007_1461cb0104_173_278.pdf

1.2. Adeola HA. Novel urinary and serological markers of prostate cancer using proteomics techniques: an important tool for early cancer diagnosis and treatment monitoring [Internet]. open.uct.ac.za; 2016. Available from: http://open.uct.ac.za/handle/11427/20955%5Cnhttp://open.uct.ac.za/bitstream/handle/11427/20955/thesis_hsf_2016_adeola_henry_ademola.pdf?sequence=1

1.3. Rouleau C, Gianolio DA, Smale R, Roth SD, Krumbholz R, Harper J, et al. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies. Mol Cancer Ther [Internet]. AACR; 2015;14(9):2081–9. Available from: http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-15-0312

1.4. *Olszanski AJ. Principles of immunotherapy. J Natl Compr Canc Netw [Internet]. jnccn.org; 2015 May;13(5 Suppl):670–2. Available from:* http://www.jnccn.org/content/13/5S/670.short

1.5. *Adrian B, Obrocea M, Marincola F, editors. Ch. 8: Antigen targeted synthetic vaccines for metastatic cancer. Cancer vaccines: from research to clinical practice. illustrate. CRC Press; 2015. p. 123.*

1.6. *Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther [Internet]. online.liebertpub.com; 2014;25(4):301–17. Available from:* http://online.liebertpub.com/doi/abs/10.1089/hum.2013.235

1.7. *Fioretti D, Iurescia S, Rinaldi M. Recent advances in design of immunogenic and effective naked DNA vaccines against cancer. Recent Pat Anticancer Drug Discov [Internet]. ingentaconnect.com; 2014 Jan;9(1):66–82. Available from:* http://www.ncbi.nlm.nih.gov/pubmed/23444943

1.8. *Rausch S, Schwentner C, Stenzl A, Bedke J. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccines Immunother [Internet]. Taylor & Francis; 2014;10(11):3146–52. Available from:* http://www.tandfonline.com/doi/abs/10.4161/hv.29553

1.9. *Zare H, Rajabibazl M, Rasooli I, Ebrahimizadeh W, Bakherad H, Ardakani LS, et al. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells. Int J Biol Markers [Internet]. researchgate.net; 2014;29(2):169–79. Available from:* https://www.researchgate.net/profile/Hamid_Bakherad/publication/259725614_Production_of_nanobodies_against_prostate-specific_membrane_antigen_(PSMA)_recognizing_LnCaP_cells/links/0f3175348f7bb364e2000000.pdf

1.10. *Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Fridman WH. DNA vaccines for cancer therapy. Oncoimmunology [Internet]. Springer; 2014;(February):1–10. Available from:* http://link.springer.com/chapter/10.1007/978-1-4471-4372-7_17

1.11. *Hannigan GD, Weiner DB. 19: PROGRESS IN DNA VACCINE APPROACHES FOR CANCER IMMUNOTHERAPY. In: Scherman D, editor. Advanced Textbook on Gene Transfer, Gene Therapy and Genetic Pharmacology: Principles, Delivery and Pharmacological and Biomedical Applications of Nucleotide-Based Therapies [Internet]. World Scientific; 2014. p. 331–59. Available from:* https://books.google.bg/books?id=99C3CgAAQBAJ&q=Todorova#v=snippet&q=Todorova&f=false

1.12. *Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology [Internet]. Taylor & Francis; 2013;2(4):e23803. Available from:* http://www.ncbi.nlm.nih.gov/pubmed/23734328%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3654598%5Cnhttp://www.tandfonline.com/doi/abs/10.4161/onci.23803

1.13. *Yan J, Pankhong P, Shin TH, Obeng-Adjei N, Morrow MP, Walters JN, et al. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase*

stimulates potent antitumor immunity. Cancer Immunol Res [Internet]. AACR; 2013;1(3):179–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24777680%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4096936

1.14. *Olson B, McNeel D. Ch. Engineering DNA Vaccines for Cancer Therapy. In: Cai W, editor. Engineering in Translational Medicine [Internet]. illustrate. Springer Science & Business Media; 2013. p. 468. Available from:* https://books.google.bg/books?id=3OG2BAAAQBAJ&dq=Engineering+in+Translational+Medicine&q=Todorova#v=snippet&q=Todorova&f=false

1.15. *Smith MH. Stem Cell Patent. Stem Cell [Internet]. 2013;4(3):142–60. Available from:* http://www.sciencepub.net/stem/stem0403/008_1520stem0403_142_160.pdf

1.16. *de Gruijl TD, van de Ven R. Chapter six--Adenovirus-based immunotherapy of cancer: promises to keep. Adv Cancer Res [Internet]. books.google.com; 2012;115:147–220. Available from:* http://www.sciencedirect.com/science/article/pii/B9780123983428000069

1.17. *Ahmad S, Sweeney P, Sullivan GC, Tangney M. DNA vaccination for prostate cancer, from preclinical to clinical trials where-we stand? Genet Vaccines Ther [Internet]. gvt-journal.biomedcentral.com; 2012;10(1):9. Available from:* https://gvt-journal.biomedcentral.com/articles/10.1186/1479-0556-10-9

1.18. *Aldrich JF. A mechanistic analysis of DNA vaccine-induced tumor immunity against the viral oncoprotein simian virus 40 large tumor antigen [Internet]. ttu-ir.tdl.org; 2012. Available from:* https://ttu-ir.tdl.org/ttu-ir/handle/2346/45189

1.19. *Smith MH. Neuro Stem Cell. Stem Cell [Internet]. 2012;3(4):126–79. Available from:* http://www.sciencepub.net/stem/stem0304/005_1426stem0304_126_179.pdf

1.20. *Smith MH. Cancer Stem Cells. Cancer Biol [Internet]. 2012;2(4):1–91. Available from:* http://www.cancerbio.net/cb/cb0204/001_1481cb0204_1_91.pdf

1.21. *Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother [Internet]. ncbi.nlm.nih.gov; 2011;34(7):556–67. Available from:* http://www.ncbi.nlm.nih.gov/pubmed/21760528%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3709852

1.22. *Aurisicchio L, Ciliberto G. Emerging cancer vaccines: The promise of genetic vectors. Cancers (Basel) [Internet]. mdpi.com; 2011;3(3):3687–713. Available from:* http://www.mdpi.com/2072-6694/3/3/3687/htm

1.23. *Wolf P. Ch. Prostate Specific Membrane Antigen as Biomarker and Therapeutic Target for Prostate Cancer. In: Spiess P, editor. Prostate Cancer - Diagnostic and Therapeutic Advances. Inst za onkologiju i radiol; 2011. p. 89.*

1.24. *Smith MH. Cancer Surgery. Cancer Biol [Internet]. 2011;1(4):173–278. Available from:* http://www.cancerbio.net/cb/cb0104/007_1461cb0104_173_278.pdf

1.25. *Pinto EF, Matta NE, Da-Cruz AM. Vaccines: Progress and challenges for the control of preventable diseases | Vacinas: Progressos e novos desafios para o controle de doenças imunopreveníveis. Acta Biol Colomb [Internet]. revistas.unal.edu.co; 2011;16(3):197–211. Available from:* http://www.revistas.unal.edu.co/index.php/actabiol/article/view/20063

1.26. *Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. JBiomedBiotechnol [Internet]. downloads.hindawi.com; 2010;2010(1110–7251 (Electronic)):174378. Available from:* http://downloads.hindawi.com/journals/biomed/2010/174378.pdf

1.27. *Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC. Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol [Internet]. downloads.hindawi.com; 2010;2010. Available from:* http://downloads.hindawi.com/journals/cdi/2010/697158.pdf

1.28. *Eschenburg G, Stermann A, Preissner R, Meyer HA, Lode HN. DNA vaccination: Using the patient's immune system to overcome cancer. Clin Dev Immunol [Internet]. downloads.hindawi.com; 2010;2010. Available from:* http://downloads.hindawi.com/journals/cdi/2010/169484.pdf

1.29. *Van Luijn MM, Chamuleau MED, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, et al. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica [Internet]. haematologica.org; 2010;95(3):485–93. Available from:* http://www.haematologica.org/content/95/3/485.short

1.30. *Bot A, Qiu Z, Wong R, Obrocea M, Smith K a. Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity. J Transl Med [Internet]. … -medicine.biomedcentral.com; 2010;8(1):132. Available from:* http://www.translational-medicine.com/content/8/1/132

1.31. *Kashani RMG. Engineered Antibody and Neuropeptide Mediated Radionuclide Targeting in Prostate Cancer [Internet]. qmro.qmul.ac.uk; 2010. Available from:* https://qmro.qmul.ac.uk/jspui/handle/123456789/574

1.32. *Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets [Internet]. ingentaconnect.com; 2009;10(2):118–25. Available from:* http://www.ingentaconnect.com/content/ben/cdt/2009/00000010/00000002/art00006

1.33. *Buhler P, Wolf P, Elsasser-Beile U. Targeting the prostate-specific membrane antigen for prostate cancer therapy [Internet]. Immunotherapy. Future Medicine; 2009. 471-481 p. Available from:* http://www.ncbi.nlm.nih.gov/pubmed/20635963

1.34. *Mastini C, Martinengo C, Inghirami G, Chiarle R. Anaplastic lymphoma kinase: An oncogene for tumor vaccination. J Mol Med [Internet]. Springer; 2009;87(7):669–77. Available from:* http://link.springer.com/article/10.1007/s00109-009-0460-5

1.35. *Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer [Internet]. nature.com;*

2008;8(2):108–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18219306

1.36. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA-and messenger RNA-based anti-cancer vaccination. Immunol Lett [Internet]. Elsevier; 2008; Available from: http://www.sciencedirect.com/science/article/pii/S0165247807002556

1.37. Assudani D, Mcardile S, Ahmad M, Li G, Rees R, Ali S. Ch 8. Vaccination strategies for malignant diseases. In: Price P, Sikora K, Illidge T, editors. Treatment of Cancer. Fifth Edit. CRC Press; 2008. p. 184.

1.38. Lowe D, Shearer M, Jumper C, Zhou E, Kennedy R. Ch. Plasmid DNA as Prophylactic and Therapeutic Vaccines. In: Georg L, editor. Plasmids: current research and future trends [Internet]. illustrate. Horizon Scientific Press; 2008. p. 238, 251. Available from: https://books.google.bg/books?id=sjg4GjaKTBwC&dq=Plasmids%3A+current+research+and+future+trends&q=Todorova#v=snippet&q=Todorova&f=false

1.39. Olson WC, Heston WDW, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials [Internet]. ingentaconnect.com; 2007;2:182–90. Available from: http://www.ingentaconnect.com/content/ben/rrct/2007/00000002/00000003/art00004

1.40. Felicetti P, Mennecozzi M, Barucca A, Montgomery S, Orlandi F, Manova K, et al. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag. Cytotherapy [Internet]. Taylor & Francis; 2007;9(1):23–34. Available from: http://www.tandfonline.com/doi/abs/10.1080/14653240601048369

1.41. Mlčochová P, Plechanovová A, Bařinka C, Mahadevan D, Saldanha JW, Rulíšek L, et al. Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis. FEBS J [Internet]. Wiley Online Library; 2007;274(18):4731–41. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2007.06021.x/full

1.42. Hamsher C, Smith AM, Dehqanzada ZA, Khoo S, Ponniah S, Peoples GE, et al. Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients. Cancer Immunol Immunother [Internet]. Springer; 2007;56(11):1711–21. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17440722

1.43. Basler M, Groettrup M. Advances in prostate cancer immunotherapies. Drugs Aging [Internet]. 2007;24(3):197–221. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17362049

1.44. Hofmeister V, Vetter C, Schrama D, Bröcker EB, ... Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer Immunol ... [Internet]. Springer; 2006; Available from: http://link.springer.com/article/10.1007/s00262-005-0070-1

1.45. Ward K a, Stewart L a, Schwarer a P. CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy. Cytotherapy [Internet]. Taylor & Francis;

2006;8(2):130–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16698686

1.46. QI HFT. Development of DNA vaccines for allergic Asthma [Internet]. scholarbank.nus.sg; 2006. Available from: http://scholarbank.nus.sg/handle/10635/27870

1.47. Payton LA. Immunologic Characterization of Tumor Protein D52 [Internet]. ttu-ir.tdl.org; 2006. Available from: https://ttu-ir.tdl.org/ttu-ir/handle/2346/23024

1.48. Havranek EG, Whelan MA, Greenhalgh R, Dalgleish AG, Pandha H. Advances in prostate cancer immunotherapy. Oncology [Internet]. Springer; 2002;11:35–45. Available from: http://link.springer.com/article/10.2165/00002512-200724030-00003

Цитирана публикация:

2. Karaivanov, M., **Todorova, K.**, Kuzmanov, A. and Hayrabedyan, S. (**2007**) 'Quantitative immunohistochemical detection of the molecular expression patterns in proliferative inflammatory atrophy', *Journal of Molecular Histology*, 38(1), pp. 1–11. doi: 10.1007/s10735-006-9070-5.

е цитирана от (9):

2.1. Bostwick DG, Hull D, Ma J, Hossain D. Ch. 8: Non-neoplastic diseases of the prostate. In: Bostwick DG, Liang C, editors. Urological Surgical Pathology [Internet]. 3, revised ed. Elsevier Health Sciences; 2014. p. 407. Available from: https://books.google.bg/books?id=wrHQAgAAQBAJ&dq=Urologic+surgical+pathology.%22+%282014%29%2C&q=Todorova#v=snippet&q=Todorova&f=false

2.2. Gobbo MG, Ribeiro DL, Taboga SR, de Almeida EA, Goes RM. Oxidative stress markers and apoptosis in the prostate of diabetic rats and the influence of vitamin C treatment. J Cell Biochem [Internet]. 2012 [cited 2016 Jan 5];113(7):2223–33. Available from: http://onlinelibrary.wiley.com/doi/10.1002/jcb.24092/full

2.3. Bostwick DG, Cheng L. Precursors of prostate cancer. Histopathology [Internet]. 2012 [cited 2016 Jan 5];60(1):4–27. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.2011.04007.x/full

2.4. Abd El-Haleem MR, Zidan RA. Effect of experimentally induced diabetes on adult albino rats' ventral prostate gland and role of selenium. Egypt J Histol [Internet]. 2011 Jun [cited 2016 Jan 5];34(2):311–22. Available from: http://journals.lww.com/ejhistology/Abstract/2011/06000/Effect_of_experimentally_induced_diabetes_on_adult.15.aspx

2.5. Schlücker S, Salehi M, Bergner G, Schütz M, Ströbel P, Marx A, et al. Immuno-surface-enhanced coherent anti-Stokes Raman scattering microscopy: Immunohistochemistry with target-specific metallic nanoprobes and nonlinear Raman microscopy. Anal Chem [Internet]. 2011 [cited 2016 Jan 5];83(18):7081–5. Available from: http://pubs.acs.org/doi/abs/10.1021/ac201284d

2.6. Berretta R, Moscato P. Cancer biomarker discovery: The entropic hallmark. PLoS One [Internet]. 2010 [cited 2016 Jan 5];5(8). Available from: http://dx.plos.org/10.1371/journal.pone.0012262

2.7. *Ribeiro DL, Marques SFG, Alberti S, Spadella CT, Manzato AJ, Taboga SR, et al. Malignant lesions in the ventral prostate of alloxan-induced diabetic rats. Int J Exp Pathol [Internet]. 2008 Jul 17 [cited 2016 Jan 5];89(4):276–83. Available from:* http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2613.2008.00591.x/pdf

2.8. *Wang W. Inflammation and Prostatic Carcinogenesis–a Morphological Study of the Human Prostate [Internet]. University of Gothenburg. Sahlgrenska Academy; 2008 [cited 2016 Jan 5]. Available from:* https://gupea.ub.gu.se/handle/2077/9634

2.9. *Bostwick DG, Qian J, Hossain D. Ch. 8: Non-neoplastic diseases of the prostate. In: Bostwick DG, Liang C, editors. Urological Surgical Pathology [Internet]. illustrate. Elsevier Health Sciences; 2008. p. 429. Available from:* https://books.google.bg/books?lr=&id=z7AA-DS0VegC&dq=David+G.+Bostwick.+Non-neoplastic+diseases+of+the+prostate.%2C+2008.+Urological+Surgical+Pathology+Elsevier+&q=Todorova#v=snippet&q=Todorova&f=false

Цитирана публикация:

3. Michailova, P., **Todorova, K**. and White, K. (**2002**) 'The effect of lead on the salivary gland chromosomes of Glyptotendipes salinus Michailova (Chironomidae, Diptera)', *Biologia, Bratislava*, 57(3), pp. 357–365. Available at: https://www.researchgate.net/profile/Paraskeva_Michailova/publication/291975271_2002124Michailovaetal_Biologia_Bratislava/links/56a8857d08ae997e22bd3cf2.pdf

е цитирана от (9):

3.1. *Bhaduri S, Sarkar P, Ghosh C, Midya T. Response of the chironomid larvae to the environmental condition: a study on the polytene chromosomes of Chironomus striatipennis (KIEFFER). The Ecoscan [Internet]. 2011;5(1–2):75–80. Available from:* http://www.thebioscan.in/Journals_PDF/6305- P. SARKAR.pdf

3.2. *Ilkova J. THE EFFECT OF LEAD ON THE POLYTENE CHROMOSOMES OF CHIRONOMUS PIGER STRENZKE (DIPTERA, CHIRONOMIDAE). Proc balkon Sci Conf ... [Internet]. Citeseer; Available from:* http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.569.838&rep=rep1&type=pdf

3.3. *Karmokov M, Akkizov AY. Karyotype characteristics, larval morphology and chromosomal polymorphism peculiarities of Glyptotendipes salinus Michailova, 1983 (Diptera, Chironomidae) from Tambukan Lake, Central Caucasus. Comp Cytogenet [Internet]. compcytogen.pensoft.net; 2016;10((4)):571–85. Available from:* http://compcytogen.pensoft.net/article_preview.php?id=9400

3.4. *Midya T, Sarkar P, Bhaduri S, Mazumdar A. Fragmentation of polytene chromosomes of chironomus striatipennis (kieffer) as a mark of heavy metal toxicity in aquatic habitats [Internet]. thebioscan.in; 2013. 1075-1078 p. Available from:* http://thebioscan.in/Journal Supplement/83Sup23 T. MIDYA.pdf

3.5. *Midya T, Bhaduri S, Sarkar P, Words KEY. Failure in Somatic Pairing of 4 Th Chromosome in (Diptera : Chironomidae). The Bioscan [Internet]. thebioscan.in;*

2012;7(2):321–4. Available from: http://www.thebioscan.in/Journals_PDF/7232-TRILOCHAN MIDYA.pdf

3.6. Mishra N, Srivastava R, Agrawal UR, Tewari RR. An insight into the genotoxicity assessment studies in dipterans. Mutat Res Mutat Res [Internet]. Elsevier; 2016; Available from: http://www.sciencedirect.com/science/article/pii/S1383574216301144

3.7. Sarkar P, Bhaduri S, Ghosh C, Midya T. a Study on the Polymorphic Fourth Chromosome of. The Bioscan [Internet]. thebioscan.in; 2011;6(3):383–7. Available from: http://www.thebioscan.in/Journals_PDF/6305- P. SARKAR.pdf

3.8. Sarkar P, Bhaduri S, Ghosh C, Midya T. the Species of Chironomus As Biosensor in Detecting Environmental Pollution: a Study on Chironomus Striatipennis Kieffer (Diptera: Chironomidae). The Ecoscan [Internet]. 2011;1:363–8. Available from: http://theecoscan.in/journalpdf/spl2011_v1-62 parantap sarkar.pdf

3.9. Tollett VD. A multi-tiered chemical and ecological assessment of southern Alabama streams [Internet]. gradworks.umi.com; 2008. Available from: http://gradworks.umi.com/14/56/1456286.html

Цитирана публикация:

4. **Todorova K**, Zoubak S, Mincheff M, Kyurkchiev S. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines. *Anticancer Res* [Internet]. ar.iiarjournals.org; **2005**;25(6 C):4727–32. Available from: http://ar.iiarjournals.org/content/25/6C/4727.short.

е цитирана от (9):

4.1. Галкін ОЮ. Порівняльна характеристика методів еПітоПного картування антигенів Протеїнової Природи. irbis-nbuv.gov.ua [Internet]. Available from: http://www.irbis-nbuv.gov.ua/cgi-bin/irbis_nbuv/cgiirbis_64.exe?C21COM=2&I21DBN=UJRN&P21DBN=UJRN&IMAGE_FILE_DOWNLOAD=1&Image_file_name=PDF/BioChem_2014_86_4_19.pdf

4.2. Doonan BP, Haque A. Prostate cancer immunotherapy: exploiting the HLA class II pathway in vaccine design. J Clin Cell Immunol [Internet]. ncbi.nlm.nih.gov; 2015; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721631/

4.3. Галкін ОЮ. Біотехнологія та біоаналітична стандартизація засобів імуноферментної діагностики [Internet]. rada.kpi.ua; 2015. Available from: http://rada.kpi.ua/files/dissertation/dis_Galkin_O.Y.pdf

4.4. Cohen EP, Chopra A, O-Sullivan IS, Kim TS. Enhancing cellular cancer vaccines [Internet]. Future Medicine; 2009. Available from: http://www.futuremedicine.com/doi/abs/10.2217/IMT.09.4

4.5. Steinaa L, Rasmussen PB, Gautam A, ... Breaking B-cell Tolerance and CTL Tolerance in three OVA-transgenic Mouse Strains Expressing Different Levels of OVA. Scand J

... [Internet]. Wiley Online Library; 2008; Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3083.2007.02045.x/full

4.6. Mirochnik Y, Rubenstein M, Guinan P. Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles. J Drug Target [Internet]. Taylor & Francis; 2007; Available from: http://www.tandfonline.com/doi/abs/10.1080/10611860701350099

4.7. Slovin SF. Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome. Clin Adv Hematol Oncol [Internet]. 2007 Dec;5(12):972–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18277959

4.8. Slovin SF. Targeting Extracellular Molecules in Prostate Cancer—Mechanisms to Inhibit Entry into the Cell-Signaling Abyss. In: Dawson NA, Kelly WK, editors. Prostate Cancer Translational and Emerging Therapies. illustrate. Taylor & Francis; 2006. p. 330.

4.9. Slovin SF. Immunologic targeting: how to channel a minimal response for maximal outcome. Curr Opin Urol [Internet]. 2006 May;16(3):179–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16679856

Цитирана публикация:

5. Hayrabedyan, S., **Todorova, K**., Pashova, S., Mollova, M. and Fernández, N. (**2012**) 'Sertoli Cell Quiescence - New Insights', *American Journal of Reproductive Immunology*, 68(6), pp. 451–455. doi: 10.1111/j.1600-0897.2012.01137.x.

е цитирана от (8):

5.1. Rodríguez H, Jara H, Legua S, Campos D, Morales J, Espinoza-Navarro O. Effects of cypermethrin on cytokeratin 8/18 and androgen receptor expression in the adult mouse Sertoli cell. Rev Int Andrología [Internet]. Elsevier; 2017 Jan; Available from: http://www.sciencedirect.com/science/article/pii/S1698031X16300802

5.2. Figueiredo AFA, França LR, Hess RA, Costa GMJ. Sertoli cells are capable of proliferation into adulthood in the transition region between the seminiferous tubules and the rete testis in Wistar rats. Cell Cycle [Internet]. Taylor & Francis; 2016 Sep 16;15(18):2486–96. Available from: https://www.tandfonline.com/doi/full/10.1080/15384101.2016.1207835

5.3. Oliveira PF, Martins AD, Moreira AC, Cheng CY, Alves MG. The Warburg Effect Revisited-Lesson from the Sertoli Cell. Med Res Rev [Internet]. 2015 Jan [cited 2016 Jan 5];35(1):126–51. Available from: http://onlinelibrary.wiley.com/doi/10.1002/med.21325/full

5.4. Zakhidov ST, Marshak TL. Experimental evidence of proliferation and reproduction of highly differentiated Sertoli cells. Biol Bull [Internet]. 2015 [cited 2016 Jan 5];42(4):287–95. Available from: http://link.springer.com/10.1134/S1062359015040159

5.5. *闫振龙袁莉刚， 朱峻峰， 谷来凤，. 老龄牦牛睾丸组织结构研究. 畜牧兽医学报 [Internet]. 118.145.16.233; 2015; Available from:* http://118.145.16.233/Jweb_xmsy/CN/article/downloadArticleFile.do?attachType=PDF&id=13583

5.6. *Xiao X, Mruk DD, Tang EI, Wong CKC, Lee WM, John CM, et al. Environmental toxicants perturb human Sertoli cell adhesive function via changes in F-actin organization mediated by actin regulatory proteins. Hum Reprod [Internet]. 2014 [cited 2016 Jan 5];29(6):1279–91. Available from:* http://humrep.oxfordjournals.org/content/early/2014/02/13/humrep.deu011.short

5.7. *Ahmed E a, Sfeir A, Takai H, Scherthan H. Ku70 and non-homologous end joining protect testicular cells from DNA damage. J Cell Sci [Internet]. 2013 [cited 2016 Jan 5];126(Pt 14):3095–104. Available from:* http://www.ncbi.nlm.nih.gov/pubmed/23857907

5.8. *Holembowski L. The p53 homolog p73 takes hold of the male germ line – a novel function of TAp73 in protecting sperm cell adhesion, migration and maturation within the seminiferous epithelium of the testis [Internet]. Georg August University Göttingen; 2012 [cited 2016 Jan 5]. Available from: https://ediss.uni-goettingen.de/bitstream/handle/11858/00-1735-0000-0001-BC61-1/PhD-Thesis_for online publication_Lena Holembowski.pdf?sequence=1*

Цитирана публикация:

6. **Todorova, K**., Metodiev, M. V., Metodieva, G., Zasheva, D., Mincheff, M. and Hayrabedyan, S. (**2016**) 'miR-204 is dysregulated in metastatic prostate cancer in vitro', *Molecular Carcinogenesis*. Wiley Online Library, 55(2), pp. 131–147. doi: 10.1002/mc.22263.

е цитирана от (8):

6.1. *Chen X, Liu X, Liu H, Lu Y, Li Y. Reduced expression of serum miR-204 predicts poor prognosis of gastric cancer. Mol Res [Internet]. funpecrp.com.br; 2016;15(2). Available from:* http://www.funpecrp.com.br/gmr/year2016/vol15-2/pdf/gmr7702.pdf

6.2. *Li T, Pan H, Li R. The dual regulatory role of miR-204 in cancer. Tumor Biol [Internet]. Springer; 2016;37(9):11667–77. Available from:* http://link.springer.com/article/10.1007/s13277-016-5144-5

6.3. *Lee H, Lee S, Bae H, Kang H-S, Kim SJ. Genome-wide identification of target genes for miR-204 and miR-211 identifies their proliferation stimulatory role in breast cancer cells. Sci Rep [Internet]. ncbi.nlm.nih.gov; 2016;6:25287. Available from:* http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4848534&tool=pmcentrez&rendertype=abstract

6.4. *Wang X, Yang B, Ma B. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. Cancer Chemother Pharmacol [Internet]. Springer; 2016;78(5):1025–31. Available from:* http://link.springer.com/article/10.1007/s00280-016-3158-8

6.5. *Devi KP, Rajavel T, Daglia M, Nabavi SF, Bishayee A, Nabavi SM. Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer. Semin Cancer Biol [Internet]. 2017 Feb; Available from:* http://linkinghub.elsevier.com/retrieve/pii/S1044579X17300172

6.6. *Liu JQ, Zhou YQ, Qian W. MiR-675 is over-expressed in patients with prostate cancer. Int J Clin Exp Pathol [Internet]. ijcep.com; 2016;(119):11814–9. Available from:* http://www.ijcep.com/files/ijcep0037652.pdf

6.7. *Butrym A, Rybka J, Baczyńska D, Tukiendorf A, Kuliczkowski K, Mazur G. Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients. J Exp Clin Cancer Res [Internet]. jeccr.biomedcentral.com; 2015 Jan 1 [cited 2016 Jan 5];34(1):68. Available from:* http://www.ncbi.nlm.nih.gov/pubmed/26126974%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4508825

6.8. *Liu J, Li Y. Trichostatin A and Tamoxifen inhibit breast cancer cell growth by MIR-204 and ERα reducing AKT/mTOR pathway. Biochem Biophys Res Commun [Internet]. 2015 Nov 13 [cited 2016 Jan 3];467(2):242–7. Available from:* http://www.sciencedirect.com/science/article/pii/S0006291X15306811

Цитирана публикация:

7. Kuzmanov, A., Hayrabedyan, S., Karaivanov, M. and **Todorova, K**. (**2007**) 'Basal cell subpopulation as putative human prostate carcinoma stem cells.', *Folia histochemica et cytobiologica*, 45(2), pp. 75–80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17597019

е цитирана от (7):

7.1. *Drewa T, Styczynski J. Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease? Med Hypotheses [Internet]. 2008 [cited 2016 Jan 5];71(5):694–9. Available from:* http://www.sciencedirect.com/science/article/pii/S0306987708002909%5Cnpapers2://publication/uuid/2D625213-1CD4-400A-8BC9-3D1FF0052BBF

7.2. *Berretta R, Moscato P. Cancer biomarker discovery: The entropic hallmark. PLoS One [Internet]. 2010 [cited 2016 Jan 5];5(8). Available from:* http://dx.plos.org/10.1371/journal.pone.0012262

7.3. *Sun F-F, Hu Y-H, Xiong L-P, Tu X-Y, Zhao J-H, Chen S-S, et al. Enhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells. Int J Clin Exp Pathol [Internet]. 2015 [cited 2016 Jan 5];8(6):6287–300. Available from:* www.ijcep.com

7.4. *Mathews LA, Crea F, Farrar WL. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation [Internet]. 2009 [cited 2016 Jan 5];78(1):1–17. Available from:* http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19443100

7.5. *熊虎黄长文， 蒋星星， 殷香保， 黄跃英， 雷康，. ＦＴＣ－ＣＤ１３３纳米微粒抑制肝癌干细胞耐药性的研究(Ｒｅｓｅａｒｃｈｏｆ ＦＴＣ－ＣＤ１３３ ｎａｎｏｐａｒｔｉｃｌｅｓｉｎｈｉｂｉｔｉｎｇｔｈｅｄｒｕｇｒｅｓｉ*

stanceoflivercancerstemcell).中国全科医学(ChineseGeneralPractice) [Internet]. 123.57.154.95; 2016;19(2): 184-189. Available from: http://123.57.154.95:8088/zgqkyx/CN/article/downloadArticleFile.do?attachType=PDF&id=1101

7.6. *Xu W, Cao L, Yin Z-F. Progress and prospects in cancer stem cell research for hepatocellular carcinoma. Chin J Cancer [Internet]. 2009 [cited 2016 Jan 5];28(9):1004–8. Available from:* http://www.cjcsysu.com/pdf/2009/9/1004.pdf

7.7. *Graziano V, De Laurenzi V. Role of p63 in cancer development. Biochim Biophys Acta - Rev Cancer [Internet]. 2011 [cited 2016 Jan 5];1816(1):57–66. Available from:* http://www.sciencedirect.com/science/article/pii/S0304419X11000187

Цитирана публикация:

8. Spencer, P. S., Hakam, S. M., Laissue, P. P., Jabeen, A., Jain, P., Hayrabedyan, S., **Todorova, K**., Blanch, A., McElhinney, J. M. W. R., Muhandiram, N., Alkhatib, S., Dealtry, G. B., Miranda-Sayago, J. M. and Fernández, N. (**2012**) 'Key Cellular Components and Interactive Histocompatibility Molecules Regulating Tolerance to the Fetal Allograft', *American Journal of Reproductive Immunology*, 68(2), pp. 95–99. doi: 10.1111/j.1600-0897.2012.01138.x.

е цитирана от (7):

8.1. *Hakam S. The role of soluble factors affecting the major histocompatibility complex class I molecules In an IN VITRO model of the fetomaternal interface [Internet]. repository.essex.ac.uk; 2016. Available from:* http://repository.essex.ac.uk/id/eprint/17521

8.2. *Sánchez SM, Pino BD, Díaz DG, Macías AC, del Valle PL. Comportamiento de las células asesinas naturales, las dendríticas y los macrófagos, en el embarazo. Rev Cuba Hematol Inmunol y Hemoter [Internet]. scielo.sld.cu; 2016;32(1):15–29. Available from:* http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892016000100003

8.3. *Segura M. Comportamiento de las células inmunitarias innatas durante el embarazo. Rev Cuba ... [Internet]. 2015 [cited 2016 Jan 5]; Available from:* http://revhematologia.sld.cu/index.php/hih/article/view/314

8.4. *Suchard M. Immunosenescence: ageing of the immune system. S Afr Pharm J [Internet]. 2015;82(8):28–31. Available from:* http://www.sapj.co.za/index.php/SAPJ/article/viewFile/2092/3701

8.5. *Reynolds LP. Cell biology symposium: The immune system in pregnancy. J Anim Sci [Internet]. 2014 [cited 2016 Jan 5];92(5):1832–3. Available from:* https://dl.sciencesocieties.org/publications/jas/articles/92/5/1832

8.6. *Romero R, Whitten A, Korzeniewski SJ, Than NG, Chaemsaithong P, Miranda J, et al. Maternal Floor Infarction/Massive Perivillous Fibrin Deposition: A Manifestation of Maternal Antifetal Rejection? Am J Reprod Immunol [Internet]. 2013 [cited 2016 Jan*

5];70(4):285–98. Available from: http://onlinelibrary.wiley.com/doi/10.1111/aji.12143/pdf

8.7. Gomez-Lopez N, Vega-Sanchez R, Castillo-Castrejon M, Romero R, Cubeiro-Arreola K, Vadillo-Ortega F, et al. Evidence for a role for the adaptive immune response in human term parturition. Am J Reprod Immunol [Internet]. 2013 [cited 2016 Jan 5];69(3):212–30. Available from: http://onlinelibrary.wiley.com/doi/10.1111/aji.12074/full.

Цитирана публикация:

9. **Todorova, K**., Mincheff, M., Hayrabedyan, S., Mincheva, J., Zasheva, D., Kuzmanov, A. and Fernández, N. (**2013**) 'Fundamental Role of microRNAs in Androgen-Dependent Male Reproductive Biology and Prostate Cancerogenesis', American Journal of Reproductive Immunology, 69(2), pp. 100–104. doi: 10.1111/j.1600-0897.2012.01139.x.

е цитирана от (5):

9.1. Holt JE, Stanger SJ, Nixon B, McLaughlin EA. Non-coding RNA in spermatogenesis and epididymal maturation. Adv Exp Med Biol [Internet]. 2016 Jan [cited 2015 Dec 16];886:95–120. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26659489

9.2. He L, Wang YL, Li Q, Yang HD, Duan ZL, Wang Q. Profiling microRNAs in the testis during sexual maturation stages in Eriocheir sinensis. Anim Reprod Sci [Internet]. 2015 [cited 2016 Jan 5];162:52–61. Available from: http://www.sciencedirect.com/science/article/pii/S0378432015300191

9.3. Wan L. Dietary Tomato and Lycopene Modulate Critical Androgen-driven mRNA and miRNA Expression in Early Prostate Carcinogenesis [Internet]. The Ohio State University; 2014 [cited 2016 Jan 5]. Available from: https://etd.ohiolink.edu/!etd.send_file?accession=osu1388489457&disposition=inline#page=37

9.4. Acton QA. Chapter 5: Reproduction and Fertility. Instite of Biology and Immunology of Reproduction, Sofia: Fundamental Role of micro-RNAs in Androgen-Dependent Male Reproductive Biology and Prostate Cancerogenesis. In: Acton QA, editor. Issues in Reproductive Medicine Research: 2013 Edition. ScholarlyEditions; 2013. p. 369.

9.5. de Sousa E. Assessment of enoxacin effect on cancer growth and microrna expression in prostate cell lines [Internet]. University of Porto; 2012 [cited 2016 Jan 5]. Available from: http://repositorio-aberto.up.pt/handle/10216/65287.

Цитирана публикация:

10. Barnea, E. R., Lubman, D. M., Liu, Y.-H., Absalon-Medina, V., Hayrabedyan, S., **Todorova, K**., Gilbert, R. O., Guingab, J. and Barder, T. J. (**2014**) 'Insight into PreImplantation Factor (PIF*) Mechanism for Embryo Protection and Development: Target

Oxidative Stress and Protein Misfolding (PDI and HSP) through Essential RIPK Binding Site', PLoS ONE. Edited by J. Yodoi. Public Library of Science, 9(7), p. e100263. doi: 10.1371/journal.pone.0100263.

е цитирана от (5):

10.1. Hakam S. The role of soluble factors affecting the major histocompatibility complex class I molecules In an IN VITRO model of the fetomaternal interface [Internet]. repository.essex.ac.uk; 2016. Available from: http://repository.essex.ac.uk/id/eprint/17521

10.2. Klein C. Maternal Recognition of Pregnancy in the Context of Equine Embryo Transfer. J Equine Vet Sci [Internet]. Elsevier; 2016;41:22–8. Available from: http://www.sciencedirect.com/science/article/pii/S0737080616300697

10.3. Allahbadia GN. Intralipid Infusion is the Current Favorite of Gynecologists for Immunotherapy. J Obstet Gynecol India [Internet]. 2015 Jul 11 [cited 2016 Jan 5];65(4):213–7. Available from: http://jogi.co.in/july_august_15/pdf/editorial.pdf

10.4. Barrientos HD. Antioxidant Effects of Seminal Plasma on Cellular Morphological Viability of Swine Semen Post-Cryopreservation. J Vet Sci Technol [Internet]. 2015 [cited 2016 Jan 5];6(3). Available from: http://www.omicsonline.org/open-access/antioxidant-effects-of-seminal-plasma-on-cellular-morphological-viability-of-swine-semen-postcryopreservation-2157-7579-1000225.php?aid=50328

10.5. Wydooghe E, Vandaele L, Heras S, De Sutter P, Deforce D, Peelman L, et al. Autocrine embryotropins revisited: How do embryos communicate with each other in vitro when cultured in groups? Biol Rev [Internet]. 2015 [cited 2016 Jan 5]; Available from: http://onlinelibrary.wiley.com/doi/10.1111/brv.12241/full.

Цитирана публикация:

11. Barnea, E. R., Kirk, D., **Todorova, K**., McElhinney, J., Hayrabedyan, S. and Fernández, N. (**2015**) 'PIF direct immune regulation: Blocks mitogen-activated PBMCs proliferation, promotes TH2/TH1 bias, independent of Ca2+', Immunobiology, 220(7), pp. 865–875. doi: 10.1016/j.imbio.2015.01.010.

е цитирана от (3):

11.1. Абламуниц ВГ. Механизмы толерантности матери к плоду: уроки молекулярной дипломатии. Probl Reproduktsii [Internet]. search.ebscohost.com; 2016;22(2):8–16. Available from: http://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=10257217&AN=117146813&h=aGPDxr0%2BpTLHFW2cAIsS%2BOu4dJ2e3zkckYTA0hd4BoK9GMw5zVpOdQYV27R074jrh5HEvLdeIaXZaZKnaNIaig%3D%3D&crl=c

11.2. Hakam S. The role of soluble factors affecting the major histocompatibility complex class I molecules In an IN VITRO model of the fetomaternal interface

[Internet]. repository.essex.ac.uk; 2016. Available from: http://repository.essex.ac.uk/id/eprint/17521

11.3. Allahbadia GN. Intralipid Infusion is the Current Favorite of Gynecologists for Immunotherapy. J Obstet Gynecol India [Internet]. 2015 Jul 11 [cited 2016 Jan 5];65(4):213–7. Available from: http://jogi.co.in/july_august_15/pdf/editorial.pdf

Цитирана публикация:

12. Hayrabedyan, S., **Todorova, K**., Zasheva, D., Moyankova, D., Georgieva, D., Todorova, J. and Djilianov, D. (**2013**) 'Haberlea Rhodopensis has Potential as a New Drug Source Based on its Broad Biological Modalities', Biotechnology & Biotechnological Equipment, 27(1), pp. 3553–3560. doi: 10.5504/BBEQ.2012.0112A

е цитирана от (3):

12.1. Todorova R, Atanasov AT. Haberlea rhodopensis: pharmaceutical and medical potential as a food additive. Nat Prod Res [Internet]. Taylor & Francis; 2015 [cited 2016 Jan 5];1–23. Available from: http://www.tandfonline.com/doi/abs/10.1080/14786419.2015.1028058

12.2. Gechev TS, Hille J, Woerdenbag HJ, Benina M, Mehterov N, Toneva V, et al. Natural products from resurrection plants: Potential for medical applications. Biotechnol Adv [Internet]. 2014 [cited 2016 Jan 5];32(6):1091–101. Available from: http://www.sciencedirect.com/science/article/pii/S073497501400041X

12.3. Grigorov B, Karamalakova Y, Nikolova G, Popov B, Ndinteh DT, Gadjeva V, et al. First Electron Paramagnetic Resonance Spectroscopy Studies on Extracts Isolated from Piptadeniastrum Africanum and Haberlea Rhodopensis. J Chem Biol Phys Sci [Internet]. 2014 [cited 2016 Jan 5];4(3):2216–26. Available from: http://www.researchgate.net/profile/Boncho_Grigorov/publication/265293379_First_Electron_Paramagnetic_Resonance_Spectroscopy_Studies_on_Extracts_Isolated_from_Piptadeniastrum_Africanum_and_Haberlea_Rhodopensis/links/5407734f0cf23d9765a9d7b6.pdf

Цитирана публикация:

13. Vangelov, I., Dineva, J., **Todorova, K**., Stefanova, T., Nikolov, G., Gulenova, D. and Ivanova, M. (**2010**) 'Relationship of follicular fluid nitric oxide concentrations with the serum steroid (progesterone, estradiol,) levels, apoptosis of granulosa luteinized cells and with the outcomes after COH/IVF', Journal of Reproductive Immunology. Elsevier, 86(2), p. 107.

е цитирана от (1):

13.1. Huang B, Li Z, Zhu L, Hu D, Liu Q, Zhu G, et al. Progesterone elevation on the day of HCG administration may affect rescue ICSI. Reprod Biomed Online [Internet].

Elsevier; 2014 Jul;29(1):88–93. Available from: http://www.sciencedirect.com/science/article/pii/S1472648314001825

14. Kistanova, E., Chervenkov, M., Shumkov, K., Peshev, R., **Todorova, K**., Hayrabedyan, S., Abadjieva, D., Shimkus, A. and Shimkiene, A. (**2015**) 'Immunostimulatory properties of Spirulina platensis against rabbit hemorrhagic disease virus', Pakistan Veterinary Journal, 35(3), pp. 379–81. Available at: http://www.pvj.com.pk/pdf-files/35_3/379-381.pdf

е цитирана от (1):

14.1. Abbas A, Iqbal Z, Abbas RZ, Khan MK, Khan JA. Immunomodulatory effects of Beta vulgaris extract against experimentally induced Coccidiosis in broiler chickens. Pak J Pharm Sci [Internet]. 2016; Available from: https://www.google.bg/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwi3quyK7vHRAhXH0xoKHd9fDFoQFggYMAA&url=http%3A%2F%2Fwww.pjps.pk%2Fwp-content%2Fuploads%2F2016%2F111952_BETA%2520VULGARIS%2520FINAL%2520IMMUNE%2520RESEARCH%2520PAPER%25

Цитирана публикация:

15. Dineva, J., Vangelov, I., Abrashev, R., **Todorova, K**., Gulenova, D., Nikolov, G., Rangelov, I., Stamenov, G., Angelova, M. and Ivanova, M. (**2011**) 'Survival role of superoxide dismutase 1 on human granulosa luteinized cells in vitro', Endocrine Regulations, 45(4), pp. 175–181. doi: 10.4149/endo_2011_04_175

е цитирана от (1):

15.1. Capcarova M, Kolesarova A, Kalafova A, Bulla J, Sirotkin A V. Adding of ascorbic acid to the culture medium influences the antioxidant status and some biochemical parameters in the hen granulosa cells. Endocr Regul [Internet]. europepmc.org; 2015 Jul;49(3):119–25. Available from: http://europepmc.org/abstract/med/26238493